Ultimately, TSGA10’s ability to enforce metabolic priorities—OXPHOS in healthy cells versus glycolysis in cancer—highlights its potential as a therapeutic target to disrupt tumor metabolic plasticity and restore mitochondrial fidelity in malignancies. This evidence concerns the gene TSGA10 and cancer.